WASHINGTON, DC — Cutaneous immune-related adverse events (cirAEs) in oncology patients receiving immune checkpoint inhibitors (ICIs) should be treated in as targeted a fashion as possible and with ...
Immune checkpoint inhibitors (ICIs) can increase life expectancy among patients who have non–small cell lung cancer (NSCLC), but they also carry the risk of immune-related adverse events. Immune ...
Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoint inhibitors (ICIs) show comparable survival outcomes whether they continued or ...
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies activating the immune system to kill tumor cells, representing a major advancement in cancer treatment. However, by activating T-cell ...
Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases and remains a leading cause of cancer mortality worldwide. Epidermal growth factor receptor (EGFR) mutations are ...
Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation Evaluating ctDNA dynamics early in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results